Table II.
Patient Population | Tryptophan [μmol/L] (fold difference from healthy controls) | Kynurenine [μmol/L] (fold difference from healthy controls) | K/T ratio [×1000] (fold difference from healthy controls) |
---|---|---|---|
Healthy Controls17 | 73 ± 14.9 | 1.92 ± 0.58 | 26.9 ± 8.1 |
Systemic Lupus Erythematosus13 | 53.9 ± 8.2 (0.77X) | 2.45 ± 0.7 (1.36X) | 43 ± 15 (1.59X) |
Rheumatoid Arthritis11 | 58 ± 19.3 (0.79X) | 2.2 ±.82 (1.14X) | 37.9 (1.41X) |
Primary Sjogren’s Syndrome33 | 75 ± 8 (0.94X) | 2.41 ± 0.7 (1.29X) | 34 ± 9 (1.41X) |
Celiac Disease18 | 35.8 ± 1.3 (0.73X) | 4.2 ± 0.27 (1.62X) | 115 ± 10.1 (1.77X) |
Septic Shock26 | |||
Deceased | 46.5 (38–59) | 8.76 (5.1–12.26) | 193.7 (124–253) |
Survivors | 51.1 (38–64) | 4.27 (2.9–6.7) | 82.4 (51–138) |
Severe/Fulminant Crohn’s | 12.7 ± 2.0 (0.37X) | 1.34 ± 0.26 (1.13X) | 117.4 ± 19.1 (3.33X) |
The comparison was generated from published literature as cited. The fold difference from healthy controls (bold) was relative to levels to the control populations from the same report. No control population was reported for the study on septic shock so a fold difference is not listed. Values are shown as mean ± standard deviation for all studies except references 18 and 26 (SEM and median quartiles, respectively).